The ideal founder archetype starts with deep technical expertise and product sense. They then develop exceptional business and commercial acumen over time, a rarer and more powerful combination than a non-technical founder learning the product.

Ovelle's founding was catalyzed by Travis Potter discovering Merrick Smela's published papers. Merrick's public presence and clear communication of his work made him discoverable. This demonstrates that for scientific entrepreneurs, sharing expertise openly is a powerful tool for inbound recruiting and fundraising.

Kevin Pojasek credits his effectiveness to a deliberate 12-year journey through diverse roles—investing, company creation, research, and clinical operations. This broad experience allows a leader to understand how all parts of the company, from high-level strategy to detailed science, fit together.

A key skill in building a deep tech team is identifying individuals who can bridge the gap between complex science and business reality. These "translators" can articulate highly technical concepts in plain English, clarifying clinical relevance and commercial viability for decision-makers.

Because in vitro gametogenesis is so new, there's no pre-existing talent pool. Ovelle's hiring strategy prioritizes finding intelligent scientists who can learn quickly. Scientific co-founder Merrick Smela emphasizes that his ability to train these new hires is a critical contribution to the company's success.

Recognizing that business leaders—not scientists—often set research priorities, Jonathan Steckbeck intentionally earned an MBA before his PhD. This nontraditional path gave him the commercial acumen to found a company where he could direct both the scientific and business strategy from day one.

The founder's number one piece of advice is to get the co-founder relationship right. While you can pivot ideas, raise more funding, or change markets, replacing a co-founder is incredibly difficult. A strong, complementary founding team is the foundation for overcoming all other startup challenges.

CEO Ron Cooper likens a biotech startup to a fire needing three elements in sync: science (the log), people (the spark), and money (oxygen). An imbalance, such as science outpacing funding, will destroy value by forcing compromised decisions.

In a tough funding climate, Ovelle successfully raised capital by focusing on investors who personally understood the problem of infertility. This strategy sidesteps the need to educate uninterested parties and instead builds a base of long-term partners who share the company's vision, proving more effective than a broad approach.